Crinetics Pharmaceuticals, Inc.

Report azionario NasdaqGS:CRNX

Capitalizzazione di mercato: US$8.8b

Crinetics Pharmaceuticals Gestione

Criteri Gestione verificati 2/4

Crinetics Pharmaceuticals Il CEO è R. Struthers, nominato in Dec2008, e ha un mandato di 17.58 anni. la retribuzione annua totale è $ 11.63M, composta da 6.2% di stipendio e 93.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.14% delle azioni della società, per un valore di $ 101.16M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.1 anni e 5.8 anni.

Informazioni chiave

R. Struthers

Amministratore delegato

US$11.6m

Compenso totale

Percentuale dello stipendio del CEO6.18%
Mandato del CEO17.6yrs
Proprietà del CEO1.1%
Durata media del management5.1yrs
Durata media del Consiglio di amministrazione5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aggiornamento narrativa • Jul 28

CRNX: Vertex Deal Price Will Anchor Shares As Endocrine Data Progresses

Crinetics Pharmaceuticals' analyst price target has reset toward the agreed $85 per share cash acquisition price, with updated models reflecting the $85.50 fair value estimate and the view from multiple firms that the Vertex deal now anchors both the upside and downside scenarios. Analyst Commentary Recent research on Crinetics Pharmaceuticals points to a clear shift in focus toward the US$85 per share cash offer from Vertex Pharmaceuticals as the key reference point for valuation.
Aggiornamento narrativa • Jul 10

CRNX: Takeover Offer And Delayed Rival Entry Will Shape Endocrine Outlook

Crinetics Pharmaceuticals' analyst fair value estimate has been trimmed from $97 to $90 as analysts recalibrate expectations around the $85 per share cash acquisition by Vertex Pharmaceuticals and the cluster of rating downgrades to Hold or Neutral that now anchor views closer to the agreed deal price. Analyst Commentary Analysts covering Crinetics Pharmaceuticals are now largely treating the stock as a merger arbitrage situation, with ratings concentrated around Hold or Neutral and price targets aligning closely with the agreed US$85 per share cash offer from Vertex Pharmaceuticals.
Seeking Alpha • Jul 07

Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Summary Vertex Pharmaceuticals Incorporated acquires Crinetics Pharmaceuticals, Inc. for $85/share, valuing the deal at ~$10bn to diversify beyond its cystic fibrosis franchise. CRNX brings PALSONIFY, a newly approved oral acromegaly therapy with blockbuster potential, and atumelnant, a Phase 3 CAH candidate, strengthening VRTX's rare disease portfolio. VRTX expects Crinetics' assets to deliver up to $5bn peak annual revenues, supporting a path toward five blockbuster products and ~$20bn revenues by 2030. The CRNX acquisition is funded by cash and debt, leveraging VRTX's strong balance sheet, with anticipated deal closure in Q3 2026 and minimal near-term financial strain. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 26

CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution

The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.
Articolo di analisi • Jun 19

Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data

Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...
Articolo di analisi • May 13

Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%

Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...
Seeking Alpha • Jan 02

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking Alpha
Seeking Alpha • Aug 12

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking Alpha
Seeking Alpha • May 23

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking Alpha

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di R. Struthers rispetto agli utili di Crinetics Pharmaceuticals?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$496m

Dec 31 2025US$12mUS$719k

-US$465m

Sep 30 2025n/an/a

-US$423m

Jun 30 2025n/an/a

-US$370m

Mar 31 2025n/an/a

-US$328m

Dec 31 2024US$11mUS$654k

-US$298m

Sep 30 2024n/an/a

-US$278m

Jun 30 2024n/an/a

-US$259m

Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$6mUS$614k

-US$215m

Sep 30 2023n/an/a

-US$199m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$175m

Dec 31 2022US$6mUS$590k

-US$164m

Sep 30 2022n/an/a

-US$150m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$119m

Dec 31 2021US$4mUS$567k

-US$108m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$4mUS$544k

-US$74m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$4mUS$542k

-US$50m

Compensazione vs Mercato: La retribuzione totale di R. ($USD 11.63M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.31M ).

Compensazione vs guadagni: La retribuzione di R. è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

R. Struthers (64 yo)

17.6yrs
Mandato
US$11,628,959
Compensazione

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
R. Struthers
Founder17.6yrsUS$11.63m1.14%
$ 101.2m
Stephen Betz
Co-Founder & Chief Scientific Officer18.5yrsUS$3.83m0.054%
$ 4.8m
Tobin Schilke
Chief Financial Officer1.4yrsUS$4.45m0.0067%
$ 596.8k
Kea Lingo
Chief Information Officer1.3yrsNessun datoNessun dato
Gayathri Diwakar
Head of Investor Relationsno dataNessun datoNessun dato
Garlan Adams
Chief Legal Officer & Corporate Secretary5.1yrsNessun datoNessun dato
Natalie Badillo
Head of Corporate Communicationsno dataNessun datoNessun dato
Adriana Cabre
Chief Human Resources Officer6.2yrsNessun datoNessun dato
Alan Krasner
Chief Endocrinologist8.1yrsUS$2.16mNessun dato
Kevin Capps
Head of Intellectual Propertyno dataNessun datoNessun dato
Chris Robillard
Chief Business Officer4.3yrsNessun datoNessun dato
Robert Cuddihy
Senior Vice President of Medical Affairs2.2yrsNessun datoNessun dato
5.1yrs
Durata media
61.5yo
Età media

Gestione esperta: Il team dirigenziale di CRNX è esperto e expertise (durata media dell'incarico 5.1 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
R. Struthers
Founder17.7yrsUS$11.63m1.14%
$ 101.2m
Wendell Wierenga
Independent Chairman of the Board10.8yrsUS$528.62k0.11%
$ 9.7m
Matthew Fust
Independent Director8.4yrsUS$498.59k0.022%
$ 1.9m
Camille Bedrosian
Independent Director5.8yrsUS$500.47k0.015%
$ 1.4m
Beverly M. Biller
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Rogerio Vivaldi Coelho
Independent Director4.5yrsUS$507.34k0.013%
$ 1.1m
Weston Nichols
Independent Director8.4yrsUS$493.84k0.015%
$ 1.4m
Stephanie Okey
Independent Director7yrsUS$500.47k0.0061%
$ 536.7k
Caren Deardorf
Independent Director4.3yrsUS$485.47k0.015%
$ 1.4m
Martin Heinrich Reincke
Member of Scientific Advisory Board4.3yrsNessun datoNessun dato
John Newell-Price
Member of Scientific Advisory Board4.3yrsNessun datoNessun dato
William Young
Member of Scientific Advisory Board4.3yrsNessun datoNessun dato
5.8yrs
Durata media
63yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CRNX sono considerati esperti (durata media dell'incarico 5.8 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/29 05:53
Prezzo dell'azione a fine giornata2026/07/29 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Crinetics Pharmaceuticals, Inc. è coperta da 22 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
David LebowitzCitigroup Inc